1
|
Bradshaw WJ, Kennedy EC, Moreira T, Smith LA, Chalk R, Katis VL, Benesch JLP, Brennan PE, Murphy EJ, Gileadi O. Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2. Structure 2024; 32:453-466.e6. [PMID: 38309262 PMCID: PMC10997489 DOI: 10.1016/j.str.2024.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 12/12/2023] [Accepted: 01/08/2024] [Indexed: 02/05/2024]
Abstract
SHIP1, an inositol 5-phosphatase, plays a central role in cellular signaling. As such, it has been implicated in many conditions. Exploiting SHIP1 as a drug target will require structural knowledge and the design of selective small molecules. We have determined apo, and magnesium and phosphate-bound structures of the phosphatase and C2 domains of SHIP1. The C2 domains of SHIP1 and the related SHIP2 modulate the activity of the phosphatase domain. To understand the mechanism, we performed activity assays, hydrogen-deuterium exchange mass spectrometry, and molecular dynamics on SHIP1 and SHIP2. Our findings demonstrate that the influence of the C2 domain is more pronounced for SHIP2 than SHIP1. We determined 91 structures of SHIP1 with fragments bound, with some near the interface between the two domains. We performed a mass spectrometry screen and determined four structures with covalent fragments. These structures could act as starting points for the development of potent, selective probes.
Collapse
Affiliation(s)
- William J Bradshaw
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK.
| | - Emma C Kennedy
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Tiago Moreira
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Luke A Smith
- Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
| | - Rod Chalk
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Vittorio L Katis
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Justin L P Benesch
- Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
| | - Paul E Brennan
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Emma J Murphy
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK
| | - Opher Gileadi
- ARUK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, Old Road Campus, University of Oxford, Oxford OX3 7FZ, UK.
| |
Collapse
|
2
|
Xu L, Xiang W, Yang J, Gao J, Wang X, Meng L, Ye K, Zhao XH, Zhang XD, Jin L, Ye Y. PHB2 promotes SHIP2 ubiquitination via the E3 ligase NEDD4 to regulate AKT signaling in gastric cancer. J Exp Clin Cancer Res 2024; 43:17. [PMID: 38200519 PMCID: PMC10782615 DOI: 10.1186/s13046-023-02937-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 12/18/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND Prohibitin 2 (PHB2) exhibits opposite functions of promoting or inhibiting tumour across various cancer types. In this study, we aim to investigate its functions and underlying mechanisms in the context of gastric cancer (GC). METHODS PHB2 protein expression levels in GC and normal tissues were examined using western blot and immunohistochemistry. PHB2 expression level associations with patient outcomes were examined through Kaplan-Meier plotter analysis utilizing GEO datasets (GSE14210 and GSE29272). The biological role of PHB2 and its subsequent regulatory mechanisms were elucidated in vitro and in vivo. GC cell viability and proliferation were assessed using MTT cell viability analysis, clonogenic assays, and BrdU incorporation assays, while the growth of GC xenografted tumours was measured via IHC staining of Ki67. The interaction among PHB2 and SHIP2, as well as between SHIP2 and NEDD4, was identified through co-immunoprecipitation, GST pull-down assays, and deletion-mapping experiments. SHIP2 ubiquitination and degradation were assessed using cycloheximide treatment, plasmid transfection and co-immunoprecipitation, followed by western blot analysis. RESULTS Our analysis revealed a substantial increase in PHB2 expression in GC tissues compared to adjacent normal tissues. Notably, higher PHB2 levels correlated with poorer patient outcomes, suggesting its clinical relevance. Functionally, silencing PHB2 in GC cells significantly reduced cell proliferation and retarded GC tumour growth, whereas overexpression of PHB2 further enhanced GC cell proliferation. Mechanistically, PHB2 physically interacted with Src homology 2-containing inositol 5-phosphatase 2 (SHIP2) in the cytoplasm of GC cells, thus leading to SHIP2 degradation via its novel E3 ligase NEDD4. It subsequently activated the PI3K/Akt signaling pathway and thus promoted GC cell proliferation. CONCLUSIONS Our findings highlight the importance of PHB2 upregulation in driving GC progression and its association with adverse patient outcomes. Understanding the functional impact of PHB2 on GC growth contributes valuable insights into the molecular underpinnings of GC and may pave the way for the development of targeted therapies to improve patient outcomes.
Collapse
Affiliation(s)
- Liang Xu
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China
- School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, NSW, 2308, Australia
| | - Wanying Xiang
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Jiezhen Yang
- Department of Pathology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, 361015, China
| | - Jing Gao
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Xinyue Wang
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Li Meng
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Kaihong Ye
- Translational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450053, Henan, China
| | - Xiao Hong Zhao
- School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, NSW, 2308, Australia
| | - Xu Dong Zhang
- School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, NSW, 2308, Australia.
- Translational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450053, Henan, China.
| | - Lei Jin
- Translational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450053, Henan, China.
- School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, 2308, Australia.
| | - Yan Ye
- Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
| |
Collapse
|
3
|
Piepgras J, Rohrbeck A, Just I, Bittner S, Ahnert-Hilger G, Höltje M. Enhancement of Phosphorylation and Transport Activity of the Neuronal Glutamate Transporter Excitatory Amino Acid Transporter 3 by C3bot and a 26mer C3bot Peptide. Front Cell Neurosci 2022; 16:860823. [PMID: 35783090 PMCID: PMC9240211 DOI: 10.3389/fncel.2022.860823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 05/16/2022] [Indexed: 11/13/2022] Open
Abstract
In primary murine hippocampal neurons we investigated the regulation of EAAT3-mediated glutamate transport by the Clostridium botulinum C3 transferase C3bot and a 26mer peptide derived from full length protein. Incubation with either enzyme-competent C3bot or enzyme-deficient C3bot156–181 peptide resulted in the upregulation of glutamate uptake by up to 22% compared to untreated cells. A similar enhancement of glutamate transport was also achieved by the classical phorbol-ester-mediated activation of protein kinase C subtypes. Yet comparable, effects elicited by C3 preparations seemed not to rely on PKCα, γ, ε, or ζ activation. Blocking of tyrosine phosphorylation by tyrosine kinase inhibitors prevented the observed effect mediated by C3bot and C3bot 26mer. By using biochemical and molecular biological assays we could rule out that the observed C3bot and C3bot 26mer-mediated effects solely resulted from enhanced transporter expression or translocation to the neuronal surface but was rather mediated by transporter phosphorylation at tyrosine residues that was found to be significantly enhanced following incubation with either full length protein or the 26mer C3 peptide.
Collapse
Affiliation(s)
- Johannes Piepgras
- Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Astrid Rohrbeck
- Institute of Toxicology, Hannover Medical School, Hanover, Germany
| | - Ingo Just
- Institute of Toxicology, Hannover Medical School, Hanover, Germany
| | - Stefan Bittner
- Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Gudrun Ahnert-Hilger
- Department of Neurobiology, Max Planck Institute for Biophysical Chemistry, University of Göttingen, Göttingen, Germany
| | - Markus Höltje
- Institut für Integrative Neuroanatomie, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- *Correspondence: Markus Höltje,
| |
Collapse
|
4
|
Abstract
The EPH receptor tyrosine kinases and their signaling partners, the EPHRINS, comprise a large class of cell signaling molecules that plays diverse roles in development. As cell membrane-anchored signaling molecules, they regulate cellular organization by modulating the strength of cellular contacts, usually by impacting the actin cytoskeleton or cell adhesion programs. Through these cellular functions, EPH/EPHRIN signaling often regulates tissue shape. Indeed, recent evidence indicates that this signaling family is ancient and associated with the origin of multicellularity. Though extensively studied, our understanding of the signaling mechanisms employed by this large family of signaling proteins remains patchwork, and a truly "canonical" EPH/EPHRIN signal transduction pathway is not known and may not exist. Instead, several foundational evolutionarily conserved mechanisms are overlaid by a myriad of tissue -specific functions, though common themes emerge from these as well. Here, I review recent advances and the related contexts that have provided new understanding of the conserved and varied molecular and cellular mechanisms employed by EPH/EPHRIN signaling during development.
Collapse
Affiliation(s)
- Jeffrey O Bush
- Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, United States; Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA, United States; Institute for Human Genetics, University of California San Francisco, San Francisco, CA, United States; Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, United States.
| |
Collapse
|
5
|
Le Coq J, López Navajas P, Rodrigo Martin B, Alfonso C, Lietha D. A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2. FASEB J 2021; 35:e21815. [PMID: 34314064 DOI: 10.1096/fj.202100561r] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 06/26/2021] [Accepted: 07/08/2021] [Indexed: 11/11/2022]
Abstract
The Src homology 2 containing inositol 5-phosphatase 2 (SHIP2) is a large multidomain enzyme that catalyzes the dephosphorylation of the phospholipid phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3 ) to form PI(3,4)P2 . PI(3,4,5)P3 is a key lipid second messenger controlling the recruitment of signaling proteins to the plasma membrane, thereby regulating a plethora of cellular events, including proliferation, growth, apoptosis, and cytoskeletal rearrangements. SHIP2, alongside PI3K and PTEN, regulates PI(3,4,5)P3 levels at the plasma membrane and has been heavily implicated in serious diseases such as cancer and type 2 diabetes; however, many aspects of its regulation mechanism remain elusive. We recently reported an activating effect of the SHIP2 C2 domain and here we describe an additional layer of regulation via the pleckstrin homology-related (PHR) domain. We show a phosphoinositide-induced transition to a high activity state of the enzyme that increases phosphatase activity up to 10-15 fold. We further show that PI(3,4)P2 directly interacts with the PHR domain to trigger this allosteric activation. Modeling of the PHR-phosphatase-C2 region of SHIP2 on the membrane suggests no major inter-domain interactions with the PHR domain, but close contacts between the two linkers offer a possible path of allosteric communication. Together, our data show that the PHR domain acts as an allosteric module regulating the catalytic activity of SHIP2 in response to specific phosphoinositide levels in the cell membrane.
Collapse
Affiliation(s)
- Johanne Le Coq
- Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Pilar López Navajas
- Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain
| | - Bárbara Rodrigo Martin
- Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain
| | - Carlos Alfonso
- Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain
| | - Daniel Lietha
- Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain
| |
Collapse
|
6
|
Wang Z, Zhou H, Yue X, Zhu J, Yang Y, Liu M. An auxiliary binding interface of SHIP2-SH2 for Y292-phosphorylated FcγRIIB reveals diverse recognition mechanisms for tyrosine-phosphorylated receptors involved in different cell signaling pathways. Anal Bioanal Chem 2021; 414:497-506. [PMID: 34021368 DOI: 10.1007/s00216-021-03373-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 04/16/2021] [Accepted: 04/23/2021] [Indexed: 12/27/2022]
Abstract
SH2 domain-containing inositol 5-phosphatase 2 (SHIP2) plays an essential role in regulating phosphatidylinositol level in human cell, and is recruited to many phosphotyrosine (pY)-dependent signal transduction pathways by the SH2 domain. In immunity signaling, immunoreceptor FcγRIIB binds to SHIP2-SH2 via its Y292-phosphorylated immunoreceptor tyrosine-based inhibitory motif (ITIM) and transmits inhibitory signal, which regulates B cell and neuronal cell activity and is associated with immune diseases and Alzheimer's disease. To date, the interaction between SHIP2 and FcγRIIB has not been analyzed from a structural point of view. Here, the binding of SHIP2-SH2 with Y292-phosphorylated FcγRIIB-ITIM was analyzed using NMR spectroscopy. The results demonstrated that SHIP2-SH2 mainly utilizes two regions including a pY-binding pocket and a specificity pocket formed by βD, βE, and EF-loop, to bind with FcγRIIB-ITIM in high affinity. In addition to the two regions, the BG-loop of SHIP2-SH2 functions as an auxiliary interface enhancing affinity. By comparing the binding of SHIP2-SH2 with ligands from FcγRIIB and c-MET, a hepatocyte growth factor receptor associated with tumorigenesis, significant differences in interface and affinity were found, suggesting that SHIP2-SH2 applies diverse patterns for binding to different ligand proteins. Moreover, S49, S51, and R70 of SHIP2 were identified to mediate the binding of both FcγRIIB and c-MET, while R28 and Q107 were found to only participate in the binding of c-MET and FcγRIIB respectively. Taken together, this study reveals the diverse mechanisms of SHIP2-SH2 for recognizing different ligands, and provides important clues for selectively manipulating various signaling pathways and specific drug design.
Collapse
Affiliation(s)
- Zi Wang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences - Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, Hubei, China.,University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Heng Zhou
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences - Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, Hubei, China.,Department of Chemistry, College of Science, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Xiali Yue
- Department of Chemistry, College of Science, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Jiang Zhu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences - Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, Hubei, China
| | - Yunhuang Yang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences - Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, Hubei, China. .,University of Chinese Academy of Sciences, Beijing, 100049, China.
| | - Maili Liu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences - Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, Hubei, China. .,University of Chinese Academy of Sciences, Beijing, 100049, China.
| |
Collapse
|
7
|
Zhou H, Yue X, Wang Z, Li S, Zhu J, Yang Y, Liu M. Expression, purification and characterization of the RhoA-binding domain of human SHIP2 in E.coli. Protein Expr Purif 2021; 180:105821. [PMID: 33421554 DOI: 10.1016/j.pep.2021.105821] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/02/2020] [Accepted: 01/03/2021] [Indexed: 11/26/2022]
Abstract
Human SH2-containing inositol 5-phosphatase 2 (SHIP2) is a multi-domain protein playing essential roles in various physiological and pathological processes. In cell polarization and migration, SHIP2 serves as a RhoA effector for manipulating the level of phosphatidylinositol 3,4,5-trisphosphate. The domain between SH2 and a potential PH-R domain of SHIP2 was suggested to bind with GTP-bound form of RhoA. However, the structure of this RhoA-binding domain (RBD) of SHIP2 and the mechanism for its binding with RhoA remain unknown. In this study, SHIP2118-298 and SHIP2176-298, two truncated proteins harboring the RBD were designed, expressed, and purified successfully in E. coli. Unexpectedly, both SHIP2118-298 and SHIP2176-298 were determined to exist as homo-dimers in solution by multi-angle light scattering. Circular dichroism spectra indicated that both proteins predominantly consisted of α-helix structure. Moreover, in pull-down experiments, both proteins could bind with GTP-bound RhoA and RhoAQ63L, a mutant mimicing the state of GTP-bound RhoA. Importantly, in silico analysis showed that the shorter truncation, SHIP2176-298, contained all ordered residues between the SH2 and the PH-R domain, and matched the RhoA effector motif 1 of PKN1 well in sequence alignment, suggesting that SHIP2176-298 is sufficient for further studies on the structure and RhoA binding of SHIP2. This work shortens and confirms the main region of SHIP2 interacting with RhoA, provides the method for sample preparation, and presents preliminary information for SHIP2-RBD structure, which will facilitate the comprehensive understanding of the structure and function of SHIP2.
Collapse
Affiliation(s)
- Heng Zhou
- Department of Chemistry, College of Science, Huazhong Agricultural University, Wuhan, 430070, China; State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China
| | - Xiali Yue
- Department of Chemistry, College of Science, Huazhong Agricultural University, Wuhan, 430070, China.
| | - Zi Wang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Shuangli Li
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China
| | - Jiang Zhu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China.
| | - Yunhuang Yang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China
| | - Maili Liu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan National Laboratory for Optoelectronics, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| |
Collapse
|
8
|
Csolle MP, Ooms LM, Papa A, Mitchell CA. PTEN and Other PtdIns(3,4,5)P 3 Lipid Phosphatases in Breast Cancer. Int J Mol Sci 2020; 21:ijms21239189. [PMID: 33276499 PMCID: PMC7730566 DOI: 10.3390/ijms21239189] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Revised: 11/25/2020] [Accepted: 12/01/2020] [Indexed: 12/31/2022] Open
Abstract
The phosphoinositide 3-kinase (PI3K)/AKT signalling pathway is hyperactivated in ~70% of breast cancers. Class I PI3K generates PtdIns(3,4,5)P3 at the plasma membrane in response to growth factor stimulation, leading to AKT activation to drive cell proliferation, survival and migration. PTEN negatively regulates PI3K/AKT signalling by dephosphorylating PtdIns(3,4,5)P3 to form PtdIns(4,5)P2. PtdIns(3,4,5)P3 can also be hydrolysed by the inositol polyphosphate 5-phosphatases (5-phosphatases) to produce PtdIns(3,4)P2. Interestingly, while PTEN is a bona fide tumour suppressor and is frequently mutated/lost in breast cancer, 5-phosphatases such as PIPP, SHIP2 and SYNJ2, have demonstrated more diverse roles in regulating mammary tumourigenesis. Reduced PIPP expression is associated with triple negative breast cancers and reduced relapse-free and overall survival. Although PIPP depletion enhances AKT phosphorylation and supports tumour growth, this also inhibits cell migration and metastasis in vivo, in a breast cancer oncogene-driven murine model. Paradoxically, SHIP2 and SYNJ2 are increased in primary breast tumours, which correlates with invasive disease and reduced survival. SHIP2 or SYNJ2 overexpression promotes breast tumourigenesis via AKT-dependent and independent mechanisms. This review will discuss how PTEN, PIPP, SHIP2 and SYNJ2 distinctly regulate multiple functional targets, and the mechanisms by which dysregulation of these distinct phosphoinositide phosphatases differentially affect breast cancer progression.
Collapse
|
9
|
Xu L, Shao Y, Ren L, Liu X, Li Y, Xu J, Ye Y. IQGAP2 Inhibits Migration and Invasion of Gastric Cancer Cells via Elevating SHIP2 Phosphatase Activity. Int J Mol Sci 2020; 21:ijms21061968. [PMID: 32183047 PMCID: PMC7139352 DOI: 10.3390/ijms21061968] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 03/09/2020] [Accepted: 03/12/2020] [Indexed: 12/30/2022] Open
Abstract
Previous studies have shown reduced expression of Src homology 2-containing inositol 5-phosphatase 2 (SHIP2) and its tumor-suppressive role in gastric cancer (GC). However, the precise role of SHIP2 in the migration and invasion of GC cells remains unclear. Here, an IQ motif containing the GTPase-activating protein 2 (IQGAP2) as a SHIP2 binding partner, was screened and identified by co-immunoprecipitation and mass spectrometry studies. While IQGAP2 ubiquitously expressed in GC cells, IQGAP2 and SHIP2 co-localized in the cytoplasm of GC cells, and this physical association was confirmed by the binding of IQGAP2 to PRD and SAM domains of SHIP2. The knockdown of either SHIP2 or IQGAP2 promoted cell migration and invasion by inhibiting SHIP2 phosphatase activity, activating Akt and subsequently increasing epithelial–mesenchymal transition (EMT). Furthermore, knockdown of IQGAP2 in SHIP2-overexpressing GC cells reversed the inhibition of cell migration and invasion by SHIP2 induction, which was associated with the suppression of elevated SHIP2 phosphatase activity. Moreover, the deletion of PRD and SAM domains of SHIP2 abrogated the interaction and restored cell migration and invasion. Collectively, these results indicate that IQGAP2 interacts with SHIP2, leading to the increment of SHIP2 phosphatase activity, and thereby inhibiting the migration and invasion of GC cells via the inactivation of Akt and reduction in EMT.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Yan Ye
- Correspondence: ; Tel.: +86-551-65161139
| |
Collapse
|
10
|
Cooke M, Baker MJ, Kazanietz MG, Casado-Medrano V. PKCε regulates Rho GTPases and actin cytoskeleton reorganization in non-small cell lung cancer cells. Small GTPases 2019; 12:202-208. [PMID: 31648598 DOI: 10.1080/21541248.2019.1684785] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Oncogenic protein kinase C epsilon (PKCε) promotes the formation of membrane ruffles and motility in non-small cell lung cancer (NSCLC) cells. We found that PKCε is down-regulated when NSCLC cells undergo epithelial-to-mesenchymal transition (EMT) in response to TGF-β, thus becoming dispensable for migration and invasion in the mesenchymal state. PKCε silencing or inhibition leads to stress fibre formation, suggesting that this kinase negatively regulates RhoA activity. Ruffle formation induced by PKCε activation in the epithelial state is dependent on PI3K, but does not involve the PI3K-dependent Rac-GEFs Ect2, Trio, Vav2 or Tiam1, suggesting alternative Rac-GEFs as mediators of this response. In the proposed model, PKCε acts as a rheostat for Rho GTPases that differs in the epithelial and mesenchymal states.
Collapse
Affiliation(s)
- Mariana Cooke
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Martin J Baker
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Marcelo G Kazanietz
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Victoria Casado-Medrano
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
11
|
Balance between dopamine and adenosine signals regulates the PKA/Rap1 pathway in striatal medium spiny neurons. Neurochem Int 2019; 122:8-18. [DOI: 10.1016/j.neuint.2018.10.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 10/02/2018] [Accepted: 10/03/2018] [Indexed: 12/19/2022]
|
12
|
Ramos AR, Ghosh S, Erneux C. The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease. J Lipid Res 2018; 60:276-286. [PMID: 30194087 DOI: 10.1194/jlr.r087908] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 09/01/2018] [Indexed: 02/06/2023] Open
Abstract
Phosphoinositides (PIs) are recognized as major signaling molecules in many different functions of eukaryotic cells. PIs can be dephosphorylated by multiple phosphatase activities at the 5-, 4-, and 3- positions. Human PI 5-phosphatases belong to a family of 10 members. Except for inositol polyphosphate 5-phosphatase A, they all catalyze the dephosphorylation of PI(4,5)P2 and/or PI(3,4,5)P3 at the 5- position. PI 5-phosphatases thus directly control the levels of PI(3,4,5)P3 and participate in the fine-tuning regulatory mechanisms of PI(3,4)P2 and PI(4,5)P2 Second messenger functions have been demonstrated for PI(3,4)P2 in invadopodium maturation and lamellipodia formation. PI 5-phosphatases can use several substrates on isolated enzymes, and it has been challenging to establish their real substrate in vivo. PI(4,5)P2 has multiple functions in signaling, including interacting with scaffold proteins, ion channels, and cytoskeleton proteins. PI 5-phosphatase isoenzymes have been individually implicated in human diseases, such as the oculocerebrorenal syndrome of Lowe, through mechanisms that include lipid control. Oncogenic and tumor-suppressive functions of PI 5-phosphatases have also been reported in different cell contexts. The mechanisms responsible for genetic diseases and for oncogenic or tumor-suppressive functions are not fully understood. The regulation of PI 5-phosphatases is thus crucial in understanding cell functions.
Collapse
Affiliation(s)
- Ana Raquel Ramos
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Somadri Ghosh
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Christophe Erneux
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
| |
Collapse
|
13
|
Wang Z, Nie Y, Zhang K, Xu H, Ramelot TA, Kennedy MA, Liu M, Zhu J, Yang Y. Solution structure of SHIP2 SH2 domain and its interaction with a phosphotyrosine peptide from c-MET. Arch Biochem Biophys 2018; 656:31-37. [PMID: 30165040 DOI: 10.1016/j.abb.2018.08.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 08/10/2018] [Accepted: 08/26/2018] [Indexed: 12/12/2022]
Abstract
SH2 domain-containing inositol 5-phosphatase 2 (SHIP2) binds with the Y1356-phosphorylated hepatocyte growth factor (HGF) receptor, c-MET, through its SH2 domain, which is essential for the role of SHIP2 in HGF-induced cell scattering and cell spreading. Previously, the experimental structure of the SH2 domain from SHIP2 (SHIP2-SH2) had not been reported, and its interaction with the Y1356-phosphorylated c-MET had not been investigated from a structural point of view. In this study, the solution structure of SHIP2-SH2 was determined by NMR spectroscopy, where it was found to adopt a typical SH2-domain fold that contains a positively-charged pocket for binding to phosphotyrosine (pY). The interaction between SHIP2-SH2 and a pY-containing peptide from c-MET (Y1356 phosphorylated) was investigated through NMR titrations. The results showed that the binding affinity of SHIP2-SH2 with the phosphopeptide is at low micromolar level, and the binding interface consists of the positively-charged pocket and its surrounding regions. Furthermore, R28, S49 and R70 were identified as key residues for the binding and may directly interact with the pY. Taken together, these findings provide structural insights into the binding of SHIP2-SH2 with the Y1356-phosphorylated c-MET, and lay a foundation for further studies of the interactions between SHIP2-SH2 and its various binding partners.
Collapse
Affiliation(s)
- Zi Wang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan Center for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Yao Nie
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan Center for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Kunxiao Zhang
- Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, Huaihai Institute of Technology, Lianyungang, 222005, China
| | - Henghao Xu
- Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, Huaihai Institute of Technology, Lianyungang, 222005, China
| | - Theresa A Ramelot
- Department of Chemistry and Biochemistry, The Northeast Structural Genomics Consortium, Miami University, Oxford, OH, 45056, United States
| | - Michael A Kennedy
- Department of Chemistry and Biochemistry, The Northeast Structural Genomics Consortium, Miami University, Oxford, OH, 45056, United States
| | - Maili Liu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan Center for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China
| | - Jiang Zhu
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan Center for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China.
| | - Yunhuang Yang
- State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan Center for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China.
| |
Collapse
|
14
|
Hoekstra E, Das AM, Willemsen M, Swets M, Kuppen PJK, van der Woude CJ, Bruno MJ, Shah JP, Ten Hagen TLM, Chisholm JD, Kerr WG, Peppelenbosch MP, Fuhler GM. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. Oncotarget 2018; 7:73525-73540. [PMID: 27716613 PMCID: PMC5341996 DOI: 10.18632/oncotarget.12321] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 09/19/2016] [Indexed: 12/13/2022] Open
Abstract
Colorectal cancer (CRC) is the second most common cause of cancer-related death, encouraging the search for novel therapeutic targets affecting tumor cell proliferation and migration. These cellular processes are under tight control of two opposing groups of enzymes; kinases and phosphatases. Aberrant activity of kinases is observed in many forms of cancer and as phosphatases counteract such "oncogenic" kinases, it is generally assumed that phosphatases function as tumor suppressors. However, emerging evidence suggests that the lipid phosphatase SH2-domain-containing 5 inositol phosphatase (SHIP2), encoded by the INPPL1 gene, may act as an oncogene. Just like the well-known tumor suppressor gene Phosphatase and Tensin Homolog (PTEN) it hydrolyses phosphatidylinositol (3,4,5) triphosphate (PI(3,4,5)P3). However, unlike PTEN, the reaction product is PI(3,4)P2, which is required for full activation of the downstream protein kinase B (PKB/Akt), suggesting that SHIP2, in contrast to PTEN, could have a tumor initiating role through PKB activation. In this work, we investigated the role of SHIP2 in colorectal cancer. We found that SHIP2 and INPPL1 expression is increased in colorectal cancer tissue in comparison to adjacent normal tissue, and this is correlated with decreased patient survival. Moreover, SHIP2 is more active in colorectal cancer tissue, suggesting that SHIP2 can induce oncogenesis in colonic epithelial cells. Furthermore, in vitro experiments performed on colorectal cancer cell lines shows an oncogenic role for SHIP2, by enhancing chemoresistance, cell migration, and cell invasion. Together, these data indicate that SHIP2 expression contributes to the malignant potential of colorectal cancer, providing a possible target in the fight against this devastating disease.
Collapse
Affiliation(s)
- Elmer Hoekstra
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Asha M Das
- Department of Surgery, Section Surgical Oncology, Laboratory Experimental Surgical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Marcella Willemsen
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Marloes Swets
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Peter J K Kuppen
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Christien J van der Woude
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Marco J Bruno
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jigisha P Shah
- Department of Chemistry, Syracuse University, Syracuse, New York, United States of America
| | - Timo L M Ten Hagen
- Department of Surgery, Section Surgical Oncology, Laboratory Experimental Surgical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - John D Chisholm
- Department of Chemistry, Syracuse University, Syracuse, New York, United States of America
| | - William G Kerr
- Department of Microbiology and Immunology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, United States of America
| | - Maikel P Peppelenbosch
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Gwenny M Fuhler
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
15
|
Ramos AR, Elong Edimo W, Erneux C. Phosphoinositide 5-phosphatase activities control cell motility in glioblastoma: Two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved. Adv Biol Regul 2018; 67:40-48. [PMID: 28916189 DOI: 10.1016/j.jbior.2017.09.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 09/01/2017] [Accepted: 09/01/2017] [Indexed: 05/15/2023]
Abstract
Inositol polyphosphate 5-phosphatases or phosphoinositide 5-phosphatases (PI 5-phosphatases) are enzymes that can act on soluble inositol phosphates and/or phosphoinositides (PIs). Several PI 5-phosphatases have been linked to human genetic diseases, in particular the Lowe protein or OCRL which is mutated in the Lowe syndrome. There are 10 different members of this family and 9 of them can use PIs as substrate. One of these substrates, PI(3,4,5)P3 binds to specific PH domains and recruits as effectors specific proteins to signaling complexes. Protein kinase B is one target protein and activation of the kinase will have a major impact on cell proliferation, survival and cell metabolism. Two other PIs, PI(4,5)P2 and PI(3,4)P2, are produced or used as substrates of PI 5-phosphatases (OCRL, INPP5B, SHIP1/2, SYNJ1/2, INPP5K, INPP5J, INPP5E). The inositol lipids may influence many aspects of cytoskeletal organization, lamellipodia formation and F-actin polymerization. PI 5-phosphatases have been reported to control cell migration, adhesion, polarity and cell invasion particularly in cancer cells. In glioblastoma, reducing SHIP2 expression can positively or negatively affect the speed of cell migration depending on the glioblastoma cell type. The two PI 5-phosphatases SHIP2 or SKIP could be localized at the plasma membrane and can reduce either PI(3,4,5)P3 or PI(4,5)P2 abundance. In the glioblastoma 1321 N1 cells, SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration.
Collapse
Affiliation(s)
- Ana Raquel Ramos
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Campus Erasme, Bldg C, 808 Route de Lennik, 1070 Brussels, Belgium
| | - William's Elong Edimo
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Campus Erasme, Bldg C, 808 Route de Lennik, 1070 Brussels, Belgium
| | - Christophe Erneux
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Campus Erasme, Bldg C, 808 Route de Lennik, 1070 Brussels, Belgium.
| |
Collapse
|
16
|
Hamze-Komaiha O, Sarr S, Arlot-Bonnemains Y, Samuel D, Gassama-Diagne A. SHIP2 Regulates Lumen Generation, Cell Division, and Ciliogenesis through the Control of Basolateral to Apical Lumen Localization of Aurora A and HEF 1. Cell Rep 2017; 17:2738-2752. [PMID: 27926875 DOI: 10.1016/j.celrep.2016.11.033] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 10/05/2016] [Accepted: 11/09/2016] [Indexed: 10/20/2022] Open
Abstract
Lumen formation during epithelial morphogenesis requires the creation of a luminal space at cell interfaces named apical membrane-initiation sites (AMISs). This is dependent upon integrated signaling from mechanical and biochemical cues, vesicle trafficking, cell division, and processes tightly coupled to ciliogenesis. Deciphering relationships between polarity determinants and lumen or cilia generation remains a fundamental issue. Here, we report that Src homology 2 domain-containing inositol 5-phosphatase 2 (SHIP2), a basolateral determinant of polarity, regulates RhoA-dependent actin contractility and cell division to form AMISs. SHIP2 regulates mitotic spindle alignment. SHIP2 is expressed in G1 phase, whereas Aurora A kinase is enriched in mitosis. SHIP2 binds Aurora A kinase and the scaffolding protein HEF1 and promotes their basolateral localization at the expense of their luminal expression connected with cilia resorption. Furthermore, SHIP2 expression increases cilia length. Thus, our findings offer new insight into the relationships among basolateral proteins, lumen generation, and ciliogenesis.
Collapse
Affiliation(s)
- Ola Hamze-Komaiha
- Université Paris-Sud, 91400 Orsay, France; Unité 1193, 94800 Villejuif, France
| | - Sokavuth Sarr
- Université Paris-Sud, 91400 Orsay, France; Unité 1193, 94800 Villejuif, France
| | | | - Didier Samuel
- Université Paris-Sud, 91400 Orsay, France; Unité 1193, 94800 Villejuif, France; AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, 94800 Villejuif, France
| | - Ama Gassama-Diagne
- Université Paris-Sud, 91400 Orsay, France; Unité 1193, 94800 Villejuif, France.
| |
Collapse
|
17
|
Ghosh S, Huber C, Siour Q, Sousa SB, Wright M, Cormier-Daire V, Erneux C. Fibroblasts derived from patients with opsismodysplasia display SHIP2-specific cell migration and adhesion defects. Hum Mutat 2017; 38:1731-1739. [DOI: 10.1002/humu.23321] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 07/13/2017] [Accepted: 08/25/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Somadri Ghosh
- IRIBHM; Campus Erasme; ULB Bâtiment C; Bruxelles Belgium
| | - Céline Huber
- Department of Medical Genetics; Reference Center for Skeletal Dysplasia; INSERM UMR 1163; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia; Paris Descartes-Sorbonne Paris Cité University; AP-HP; Institut Imagine; Paris France
- Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - Quentin Siour
- Department of Medical Genetics; Reference Center for Skeletal Dysplasia; INSERM UMR 1163; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia; Paris Descartes-Sorbonne Paris Cité University; AP-HP; Institut Imagine; Paris France
- Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - Sérgio B. Sousa
- Medical Genetics Unit; Hospital Pediátrico; Centro Hospitalare Universitário de Coimbra; Coimbra Portugal
| | - Michael Wright
- Northern Genetics Service; Newcastle-upon-Tyne Hospitals; Newcastle- upon-Tyne UK
| | - Valérie Cormier-Daire
- Department of Medical Genetics; Reference Center for Skeletal Dysplasia; INSERM UMR 1163; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia; Paris Descartes-Sorbonne Paris Cité University; AP-HP; Institut Imagine; Paris France
- Hôpital Universitaire Necker-Enfants Malades; Paris France
| | | |
Collapse
|
18
|
Abstract
During bone remodelling, osteoclasts induce chemotaxis of osteoblasts and yet maintain spatial segregation. We show that osteoclasts express the repulsive guidance factor Semaphorin 4D and induce contact inhibition of locomotion (CIL) in osteoblasts through its receptor Plexin-B1. To examine causality and elucidate how localized Plexin-B1 stimulation may spatiotemporally coordinate its downstream targets in guiding cell migration, we develop an optogenetic tool for Plexin-B1 designated optoPlexin. Precise optoPlexin activation at the leading edge of migrating osteoblasts readily induces local retraction and, unexpectedly, distal protrusions to steer cells away. These morphological changes are accompanied by reorganization of Myosin II, PIP3, adhesion and active Cdc42. We attribute the resultant repolarization to RhoA/ROCK-mediated redistribution of β-Pix, which activates Cdc42 and promotes protrusion. Thus, our data demonstrate a causal role of Plexin-B1 for CIL in osteoblasts and reveals a previously unknown effect of Semaphorin signalling on spatial distribution of an activator of cell migration.
Collapse
|
19
|
Tumor Cell Invadopodia: Invasive Protrusions that Orchestrate Metastasis. Trends Cell Biol 2017; 27:595-607. [PMID: 28412099 DOI: 10.1016/j.tcb.2017.03.003] [Citation(s) in RCA: 250] [Impact Index Per Article: 35.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 03/09/2017] [Accepted: 03/13/2017] [Indexed: 12/26/2022]
Abstract
Invadopodia are a subset of invadosomes that are implicated in the integration of signals from the tumor microenvironment to support tumor cell invasion and dissemination. Recent progress has begun to define how tumor cells regulate the plasticity necessary for invadopodia to assemble and function efficiently in the different microenvironments encountered during dissemination in vivo. Exquisite mapping by many laboratories of the pathways involved in integrating diverse invadopodium initiation signals, from growth factors, to extracellular matrix (ECM) and cell-cell contact in the tumor microenvironment, has led to insight into the molecular basis of this plasticity. Here, we integrate this new information to discuss how the invadopodium is an important conductor that orchestrates tumor cell dissemination during metastasis.
Collapse
|
20
|
Thomas MP, Erneux C, Potter BVL. SHIP2: Structure, Function and Inhibition. Chembiochem 2017; 18:233-247. [DOI: 10.1002/cbic.201600541] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Mark P. Thomas
- Department of Pharmacy and Pharmacology; University of Bath; Claverton Down Bath BA2 7AY UK
| | - Christophe Erneux
- I.R.I.B.H.M.; Université Libre de Bruxelles; Campus Erasme 808 Route de Lennik 1070 Brussels Belgium
| | - Barry V. L. Potter
- Drug Discovery and Medicinal Chemistry; Department of Pharmacology; University of Oxford; Mansfield Road Oxford OX1 3QT UK
| |
Collapse
|
21
|
Awad A, Gassama-Diagne A. PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis. World J Hepatol 2017; 9:18-29. [PMID: 28105255 PMCID: PMC5220268 DOI: 10.4254/wjh.v9.i1.18] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 09/10/2016] [Accepted: 11/02/2016] [Indexed: 02/06/2023] Open
Abstract
Hepatitis C virus (HCV) infects hepatocytes, polarized cells in the liver. Chronic HCV infection often leads to steatosis, fibrosis, cirrhosis and hepatocellular carcinoma, and it has been identified as the leading cause of liver transplantation worldwide. The HCV replication cycle is dependent on lipid metabolism and particularly an accumulation of lipid droplets in host cells. Phosphoinositides (PIs) are minor phospholipids enriched in different membranes and their levels are tightly regulated by specific PI kinases and phosphatases. PIs are implicated in a vast array of cellular responses that are central to morphogenesis, such as cytoskeletal changes, cytokinesis and the recruitment of downstream effectors to govern mechanisms involved in polarization and lumen formation. Important reviews of the literature identified phosphatidylinositol (PtdIns) 4-kinases, and their lipid products PtdIns(4)P, as critical regulators of the HCV life cycle. SH2-containing inositol polyphosphate 5-phosphatase (SHIP2), phosphoinositide 3-kinase (PI3K) and their lipid products PtdIns(3,4)P2 and PtdIns(3,4,5)P3, respectively, play an important role in the cell membrane and are key to the establishment of apicobasal polarity and lumen formation. In this review, we will focus on these new functions of PI3K and SHIP2, and their deregulation by HCV, causing a disruption of apicobasal polarity, actin organization and extracellular matrix assembly. Finally we will highlight the involvement of this pathway in the event of insulin resistance and nonalcoholic fatty liver disease related to HCV infection.
Collapse
|
22
|
Paul F, Zauber H, von Berg L, Rocks O, Daumke O, Selbach M. Quantitative GTPase Affinity Purification Identifies Rho Family Protein Interaction Partners. Mol Cell Proteomics 2016; 16:73-85. [PMID: 27852748 DOI: 10.1074/mcp.m116.061531] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 10/27/2016] [Indexed: 12/17/2022] Open
Abstract
Although Rho GTPases are essential molecular switches involved in many cellular processes, an unbiased experimental comparison of their interaction partners was not yet performed. Here, we develop quantitative GTPase affinity purification (qGAP) to systematically identify interaction partners of six Rho GTPases (Cdc42, Rac1, RhoA, RhoB, RhoC, and RhoD), depending on their nucleotide loading state. The method works with cell line or tissue-derived protein lysates in combination with SILAC-based or label-free quantification, respectively. We demonstrate that qGAP identifies known and novel binding partners that can be validated in an independent assay. Our interaction network for six Rho GTPases contains many novel binding partners, reveals highly promiscuous interaction of several effectors, and mirrors evolutionary relationships among Rho GTPases.
Collapse
Affiliation(s)
| | | | | | - Oliver Rocks
- §Spatio-Temporal Control of Rho GTPase Signaling
| | - Oliver Daumke
- ¶Crystallography, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, D-13092 Berlin, Germany
| | | |
Collapse
|
23
|
Fradet A, Fitzgerald J. INPPL1 gene mutations in opsismodysplasia. J Hum Genet 2016; 62:135-140. [PMID: 27708270 DOI: 10.1038/jhg.2016.119] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 09/05/2016] [Accepted: 09/08/2016] [Indexed: 01/19/2023]
Abstract
The INPPL1 (inositol polyphosphate phosphatase-like 1) gene encodes the inositol phosphatase, SHIP2 (for src homology 2 domain-containing inositol phosphatase 2). SHIP2 functions to dephosphorylate, and negatively regulate, the lipid second messenger phosphatidylinositol (3,4,5)P3. SHIP2 has been well studied in the area of insulin resistance and obesity but has roles in cancer and other disorders. Recently, it was reported that mutations in INPPL1 cause opsismodysplasia, a rare, autosomal recessive severe skeletal dysplasia. This review focuses on the mutations associated with opsismodysplasia and explores the role of INPPL1/ SHIP2 in skeletal development.
Collapse
Affiliation(s)
- Anaïs Fradet
- Department of Orthopedic Surgery, Bone and Joint Center, Henry Ford Hospital System, Detroit, MI, USA
| | - Jamie Fitzgerald
- Department of Orthopedic Surgery, Bone and Joint Center, Henry Ford Hospital System, Detroit, MI, USA
| |
Collapse
|
24
|
The SHIP2 interactor Myo1c is required for cell migration in 1321 N1 glioblastoma cells. Biochem Biophys Res Commun 2016; 476:508-514. [DOI: 10.1016/j.bbrc.2016.05.154] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Accepted: 05/28/2016] [Indexed: 12/29/2022]
|
25
|
Yura Y, Amano M, Takefuji M, Bando T, Suzuki K, Kato K, Hamaguchi T, Hasanuzzaman Shohag M, Takano T, Funahashi Y, Nakamuta S, Kuroda K, Nishioka T, Murohara T, Kaibuchi K. Focused Proteomics Revealed a Novel Rho-kinase Signaling Pathway in the Heart. Cell Struct Funct 2016; 41:105-20. [PMID: 27334702 DOI: 10.1247/csf.16011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Protein phosphorylation plays an important role in the physiological regulation of cardiac function. Myocardial contraction and pathogenesis of cardiac diseases have been reported to be associated with adaptive or maladaptive protein phosphorylation; however, phosphorylation signaling in the heart is not fully elucidated. We recently developed a novel kinase-interacting substrate screening (KISS) method for exhaustive screening of protein kinase substrates, using mass spectrometry and affinity chromatography. First, we examined protein phosphorylation by extracellular signal-regulated kinase (ERK) and protein kinase A (PKA), which has been relatively well studied in cardiomyocytes. The KISS method showed that ERK and PKA mediated the phosphorylation of known cardiac-substrates of each kinase such as Rps6ka1 and cTnI, respectively. Using this method, we found about 330 proteins as Rho-kinase-mediated substrates, whose substrate in cardiomyocytes is unknown. Among them, CARP/Ankrd1, a muscle ankyrin repeat protein, was confirmed as a novel Rho-kinase-mediated substrate. We also found that non-phosphorylatable form of CARP repressed cardiac hypertrophy-related gene Myosin light chain-2v (MLC-2v) promoter activity, and decreased cell size of heart derived H9c2 myoblasts more efficiently than wild type-CARP. Thus, focused proteomics enable us to reveal a novel signaling pathway in the heart.
Collapse
Affiliation(s)
- Yoshimitsu Yura
- Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ye Y, Ge YM, Xiao MM, Guo LM, Li Q, Hao JQ, Da J, Hu WL, Zhang XD, Xu J, Zhang LJ. Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. J Gastroenterol 2016. [PMID: 26201869 DOI: 10.1007/s00535-015-1101-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The Src homology 2-containing inositol 5-phosphatase 2 (SHIP2) is implicated in diabetes, arthrosclerosis, and cancer. However, the role of SHIP2 in human gastric cancer remains unclear. METHODS The expression levels of SHIP2 in gastric cancer tissues, a panel of gastric cancer cell lines, and normal gastric epithelial cells were analyzed by immunohistochemistry (IHC), Western blot, and real-time quantitative RT-PCR (qRT-PCR). Gastric cancer cells with either overexpressed SHIP2 or co-overexpressed SHIP2 and Akt were analyzed to determine cell proliferation, colony formation, apoptosis, cell migration, and invasion assays. Normal gastric epithelial cells with knockdown SHIP2 or co-knockdown SHIP2 and Akt were subjected by anchorage-independent growth assays. The effect of SHIP2 on tumor growth in vivo was detected by xenograft tumorigenesis assays. RESULTS SHIP2 was commonly downregulated in gastric cancer compared with normal gastric mucosa, and overexpression of SHIP2 inhibited cell proliferation, induced apoptosis, suppressed cell motility and invasion in gastric cancer cells in vitro, and retarded the growth of xenograft gastric tumors in vivo, while knockdown of SHIP2 in normal gastric epithelial cells promoted anchorage-independent growth. Moreover, overexpression of SHIP2 inactivated Akt, and upregulated p21, p27, and the pro-apoptotic protein Bim. Restoring Akt activation in gastric cancer cells largely blocked the inhibition of PI3K/Akt signaling by SHIP2 and reversed the inhibitory effect of SHIP2 on tumorigenesis and proliferation. CONCLUSIONS This study demonstrates, for the first time, that SHIP2 is frequently downregulated in gastric cancer, and reduced SHIP2 expression promotes tumorigenesis and proliferation of gastric cancer via activation of the PI3K/Akt signaling.
Collapse
Affiliation(s)
- Yan Ye
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Yan Mei Ge
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Miao Miao Xiao
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Li Mei Guo
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Qun Li
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Ji Qing Hao
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China
| | - Jie Da
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China
| | - Wang Lai Hu
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China
| | - Xu Dong Zhang
- School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, 2308, Australia
| | - Jiegou Xu
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China.
| | - Lin Jie Zhang
- Department of Immunology, Anhui Medical University, Hefei, 230032, Anhui, China.
| |
Collapse
|
27
|
Edimo WE, Ghosh S, Derua R, Janssens V, Waelkens E, Vanderwinden JM, Robe P, Erneux C. SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma. J Cell Sci 2016; 129:1101-14. [DOI: 10.1242/jcs.179663] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 01/25/2016] [Indexed: 12/31/2022] Open
Abstract
Phosphoinositides, particularly PI(3,4,5)P3, and PI(4,5)P2, are recognized by SHIP2 a member of the inositol polyphosphate 5-phosphatase family. SHIP2 dephosphorylates PI(3,4,5)P3 to form PI(3,4)P2; the latter interacts with specific target proteins (e.g. lamellipodin). Although the SHIP2 preferred substrate is PI(3,4,5)P3, PI(4,5)P2 could also be dephosphorylated to PI4P. Through depletion of SHIP2 in a glioblastoma cell line 1321 N1 cells, we show that SHIP2 inhibits cell migration. In different glioblastoma cell lines and primary cultures, SHIP2 staining at the plasma membrane partly overlaps with PI(4,5)P2 immunoreactivity. PI(4,5)P2 was upregulated in SHIP2-deficient N1 cells as compared to control cells; in contrast, PI4P was very much decreased in SHIP2-deficient cells. Therefore, SHIP2 controls both PI(3,4,5)P3 and PI(4,5)P2 levels in intact cells. In N1 cells, the PI(4,5)P2 binding protein myosin-1c was identified as a new interactor of SHIP2. Regulation of PI(4,5)P2 and PI4P content by SHIP2 controls N1 cell migration through the organization of focal adhesions. Thus, our results reveal a novel role of SHIP2 in the control of PI(4,5)P2, PI4P and cell migration in PTEN-deficient glioblastoma N1 cells.
Collapse
Affiliation(s)
- William's Elong Edimo
- IRIBHM, Campus Erasme, ULB Bâtiment C, 808 route de Lennik B-1070 Bruxelles, Belgium
| | - Somadri Ghosh
- IRIBHM, Campus Erasme, ULB Bâtiment C, 808 route de Lennik B-1070 Bruxelles, Belgium
| | - Rita Derua
- Protein Phosphorylation & Proteomics Lab, Department of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Herestraat 49 PO-box 901, B-3000 Leuven, Belgium
| | - Veerle Janssens
- Protein Phosphorylation & Proteomics Lab, Department of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Herestraat 49 PO-box 901, B-3000 Leuven, Belgium
| | - Etienne Waelkens
- Protein Phosphorylation & Proteomics Lab, Department of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Herestraat 49 PO-box 901, B-3000 Leuven, Belgium
| | - Jean-Marie Vanderwinden
- Laboratory of Neurophysiology, ULB Bâtiment C, 808 route de Lennik B-1070 Bruxelles, Belgium
| | - Pierre Robe
- Génétique Humaine, GIGA center, Ulg, Belgium
| | - Christophe Erneux
- IRIBHM, Campus Erasme, ULB Bâtiment C, 808 route de Lennik B-1070 Bruxelles, Belgium
| |
Collapse
|
28
|
Iwama S, Sugimura Y, Kiyota A, Kato T, Enomoto A, Suzuki H, Iwata N, Takeuchi S, Nakashima K, Takagi H, Izumida H, Ochiai H, Fujisawa H, Suga H, Arima H, Shimoyama Y, Takahashi M, Nishioka H, Ishikawa SE, Shimatsu A, Caturegli P, Oiso Y. Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis. J Clin Endocrinol Metab 2015; 100:E946-54. [PMID: 25919460 PMCID: PMC5393526 DOI: 10.1210/jc.2014-4209] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 04/22/2015] [Indexed: 11/19/2022]
Abstract
CONTEXT Central diabetes insipidus (CDI) can be caused by several diseases, but in about half of the patients the etiological diagnosis remains unknown. Lymphocytic infundibulo-neurohypophysitis (LINH) is an increasingly recognized entity among cases of idiopathic CDI; however, the differential diagnosis from other pituitary diseases including tumors can be difficult because of similar clinical and radiological manifestations. The definite diagnosis of LINH requires invasive pituitary biopsy. OBJECTIVE The study was designed to identify the autoantigen(s) in LINH and thus develop a diagnostic test based on serum autoantibodies. DESIGN Rat posterior pituitary lysate was immunoprecipitated with IgGs purified from the sera of patients with LINH or control subjects. The immunoprecipitates were subjected to liquid chromatography-tandem mass spectrometry to screen for pituitary autoantigens of LINH. Subsequently, we made recombinant proteins of candidate autoantigens and analyzed autoantibodies in serum by Western blotting. RESULTS Rabphilin-3A proved to be the most diagnostically useful autoantigen. Anti-rabphilin-3A antibodies were detected in 22 of the 29 (76%) patients (including 4 of the 4 biopsy-proven samples) with LINH and 2 of 18 (11.1%) patients with biopsy-proven lymphocytic adeno-hypophysitis. In contrast, these antibodies were absent in patients with biopsy-proven sellar/suprasellar masses without lymphocytic hypophysitis (n = 34), including 18 patients with CDI. Rabphilin-3A was expressed in posterior pituitary and hypothalamic vasopressin neurons but not anterior pituitary. CONCLUSIONS These results suggest that rabphilin-3A is a major autoantigen in LINH. Autoantibodies to rabphilin-3A may serve as a biomarker for the diagnosis of LINH and be useful for the differential diagnosis in patients with CDI.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing/immunology
- Adaptor Proteins, Signal Transducing/metabolism
- Adult
- Animals
- Autoantibodies/blood
- Autoantigens/immunology
- Autoimmune Diseases/blood
- Autoimmune Diseases/immunology
- Autoimmune Diseases/metabolism
- Diabetes Insipidus, Neurogenic/blood
- Diabetes Insipidus, Neurogenic/diagnosis
- Diabetes Insipidus, Neurogenic/immunology
- Diabetes Insipidus, Neurogenic/metabolism
- Diagnosis, Differential
- Female
- HEK293 Cells
- Humans
- Lymphocytes/immunology
- Male
- Nerve Tissue Proteins/immunology
- Nerve Tissue Proteins/metabolism
- Pituitary Gland, Posterior/immunology
- Pituitary Gland, Posterior/metabolism
- Rats
- Rats, Sprague-Dawley
- Vesicular Transport Proteins/immunology
- Vesicular Transport Proteins/metabolism
- Young Adult
- Rabphilin-3A
Collapse
Affiliation(s)
- Shintaro Iwama
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Yoshihisa Sugimura
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Atsushi Kiyota
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Takuya Kato
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Atsushi Enomoto
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Haruyuki Suzuki
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Naoko Iwata
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Seiji Takeuchi
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Kohtaro Nakashima
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hiroshi Takagi
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hisakazu Izumida
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hiroshi Ochiai
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Haruki Fujisawa
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hidetaka Suga
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hiroshi Arima
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Yoshie Shimoyama
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Masahide Takahashi
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Hiroshi Nishioka
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - San-e Ishikawa
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Akira Shimatsu
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Patrizio Caturegli
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| | - Yutaka Oiso
- Department of Endocrinology and Diabetes (S.Iw., Y.Su., A.K., H.S., N.I., S.T., K.N., H.T., H.I., H.O., H.F., H.S., H.A., Y.O.) and Department of Pathology (T.K., A.E., M.T.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Research Center of Health, Physical Fitness and Sports (S.Iw.), Nagoya University, Nagoya 464-8601, Japan; Department of Pathology and Clinical Laboratory (Y.Sh.), Nagoya University Hospital, Nagoya 466-8560, Japan; Department of Hypothalamic and Pituitary Surgery (H.N.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Medicine (S.Is.), Jichi Medical University Saitama Medical Center, Saitama, 330-8503, Japan; Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; Department of Pathology (P.C.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Feinstone Department of Molecular Microbiology and Immunology (P.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; and Japan Hypophysitis Research Group (S.Iw., Y.Su., H.N., S.Is., A.S., Y.O.), Nagoya 466-8550, Japan
| |
Collapse
|
29
|
Kiyota A, Iwama S, Sugimura Y, Takeuchi S, Takagi H, Iwata N, Nakashima K, Suzuki H, Nishioka T, Kato T, Enomoto A, Arima H, Kaibuchi K, Oiso Y. Identification of the novel autoantigen candidate Rab GDP dissociation inhibitor alpha in isolated adrenocorticotropin deficiency. Endocr J 2015; 62:153-60. [PMID: 25346144 DOI: 10.1507/endocrj.ej14-0369] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Isolated adrenocorticotropin deficiency (IAD) is characterized by low or absent adrenocorticotropic hormone (ACTH) production. IAD is presumed to be caused in part by an autoimmune mechanism, and several lines of evidence have suggested the presence of anti-pituitary antibodies in IAD. However, the exact autoantigens remain unknown. The present study was designed to identify the autoantigen(s) in IAD using chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Rat anterior pituitary lysate was subjected to SDS-PAGE, and immunoblotting was performed using the sera from two patients with IAD and from a healthy subject. The bands detected by the patient serum samples, but not by the healthy subject sample, were excised, in-gel digested using trypsin, and subjected to LC-MS/MS analysis. On immunoblots, a 51-kDa band in the insoluble pellet was detected by the sera from the IAD patients but not from the healthy subject. Mass spectrometric analysis revealed the 51-kDa band contained Rab guanine nucleotide dissociation inhibitor (GDI) alpha. Consistent with the mass spectrometric analysis, a recombinant full-length human Rab GDI alpha was recognized by the two IAD patient samples but not by the healthy subject sample using immunoblotting. In total, anti-Rab GDI alpha antibodies were detected in serum samples from three of five patients with IAD (60%) but were absent in 5 healthy subjects. In addition, Rab GDI alpha was expressed in the anterior pituitary. In conclusion, it appears that Rab GDI alpha is a candidate autoantigen involved in IAD, and that anti-Rab GDI alpha antibodies are present predominantly in patients with IAD.
Collapse
Affiliation(s)
- Atsushi Kiyota
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The specific interaction of phosphoinositides with proteins is critical for a plethora of cellular processes, including cytoskeleton remodelling, mitogenic signalling, ion channel regulation and membrane traffic. The spatiotemporal restriction of different phosphoinositide species helps to define compartments within the cell, and this is particularly important for membrane trafficking within both the secretory and endocytic pathways. Phosphoinositide homoeostasis is tightly regulated by a large number of inositol kinases and phosphatases, which respectively phosphorylate and dephosphorylate distinct phosphoinositide species. Many of these enzymes have been implicated in regulating membrane trafficking and, accordingly, their dysregulation has been linked to a number of human diseases. In the present review, we focus on the inositol phosphatases, concentrating on their roles in membrane trafficking and the human diseases with which they have been associated.
Collapse
|
31
|
Deneubourg L, Elong Edimo W, Moreau C, Vanderwinden JM, Erneux C. Phosphorylated SHIP2 on Y1135 localizes at focal adhesions and at the mitotic spindle in cancer cell lines. Cell Signal 2014; 26:1193-203. [DOI: 10.1016/j.cellsig.2014.02.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 01/20/2014] [Accepted: 02/13/2014] [Indexed: 11/30/2022]
|
32
|
Liu L, Wang Y, Yu Q. The PI3K/Akt signaling pathway exerts effects on the implantation of mouse embryos by regulating the expression of RhoA. Int J Mol Med 2014; 33:1089-96. [PMID: 24638941 PMCID: PMC4020477 DOI: 10.3892/ijmm.2014.1701] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Accepted: 03/05/2014] [Indexed: 01/17/2023] Open
Abstract
The aim of this study was to investigate whether the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway affects the implantation of mouse embryos by regulating the expression of RhoA. The expression of PI3K, Akt, phosphorylated (p-)Akt, phosphatase and tensin homolog (PTEN) and RhoA in the uterus of mice on day 5 of pregnancy (D5) and in pseudopregnant mice was examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR), immunohistochemistry and western blot analysis. A functional analysis of these genes was also performed by the intrauterine injection with the PI3K inhibitor, LY294002, on day 2 of pregnancy (D2). The expression levels of PI3K, p-Akt, RhoA at the implantation site were higher than those at the inter-implantation site in the endometrium; however, opposite effects were observed for PTEN expression. The expression levels of the above genes in the pseudopregnant group and in the group injected with the PI3K/Akt inhibitor, LY294002, were markedly lower than those in the pregnant group. Functional experiments revealed that the number of implantation sites had been significantly decreased (P<0.05) following the intrauterine injection of the PI3K inhibitor, LY294002, on day 2 of gestation compared with the contralateral injection of phosphate-buffered saline (PBS). These results suggest that the PI3K/Akt signaling pathway affects embryo implantation by regulating the expression of RhoA.
Collapse
Affiliation(s)
- Liyuan Liu
- College of Basic Medicine, Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
| | - Yingxiong Wang
- College of Basic Medicine, Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
| | - Qiubo Yu
- Molecular Medical Laboratory, Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
| |
Collapse
|
33
|
Hwang J, Pallas DC. STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol 2014; 47:118-48. [PMID: 24333164 PMCID: PMC3927685 DOI: 10.1016/j.biocel.2013.11.021] [Citation(s) in RCA: 170] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2013] [Revised: 11/18/2013] [Accepted: 11/28/2013] [Indexed: 12/31/2022]
Abstract
The mammalian striatin family consists of three proteins, striatin, S/G2 nuclear autoantigen, and zinedin. Striatin family members have no intrinsic catalytic activity, but rather function as scaffolding proteins. Remarkably, they organize multiple diverse, large signaling complexes that participate in a variety of cellular processes. Moreover, they appear to be regulatory/targeting subunits for the major eukaryotic serine/threonine protein phosphatase 2A. In addition, striatin family members associate with germinal center kinase III kinases as well as other novel components, earning these assemblies the name striatin-interacting phosphatase and kinase (STRIPAK) complexes. Recently, there has been a great increase in functional and mechanistic studies aimed at identifying and understanding the roles of STRIPAK and STRIPAK-like complexes in cellular processes of multiple organisms. These studies have identified novel STRIPAK and STRIPAK-like complexes and have explored their roles in specific signaling pathways. Together, the results of these studies have sparked increased interest in striatin family complexes because they have revealed roles in signaling, cell cycle control, apoptosis, vesicular trafficking, Golgi assembly, cell polarity, cell migration, neural and vascular development, and cardiac function. Moreover, STRIPAK complexes have been connected to clinical conditions, including cardiac disease, diabetes, autism, and cerebral cavernous malformation. In this review, we discuss the expression, localization, and protein domain structure of striatin family members. Then we consider the diverse complexes these proteins and their homologs form in various organisms, emphasizing what is known regarding function and regulation. Finally, we explore possible roles of striatin family complexes in disease, especially cerebral cavernous malformation.
Collapse
Affiliation(s)
- Juyeon Hwang
- Department of Biochemistry and Winship Cancer Institute, and Biochemistry, Cell, Developmental Biology Graduate Program, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.
| | - David C Pallas
- Department of Biochemistry and Winship Cancer Institute, and Biochemistry, Cell, Developmental Biology Graduate Program, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.
| |
Collapse
|
34
|
Abstract
During chemotaxis, cells sense extracellular chemical gradients and position Ras GTPase activation and phosphatidylinositol (3,4,5)-triphosphate (PIP3) production toward chemoattractants. These two major signaling events are visualized by biosensors in a crescent-like zone at the plasma membrane. Here, we show that a Dictyostelium Rho GTPase, RacE, and a guanine nucleotide exchange factor, GxcT, stabilize the orientation of Ras activation and PIP3 production in response to chemoattractant gradients, and this regulation occurred independently of the actin cytoskeleton and cell polarity. Cells lacking RacE or GxcT fail to persistently direct Ras activation and PIP3 production toward chemoattractants, leading to lateral pseudopod extension and impaired chemotaxis. Constitutively active forms of RacE and human RhoA are located on the portion of the plasma membrane that faces lower concentrations of chemoattractants, opposite of PIP3 production. Mechanisms that control the localization of the constitutively active form of RacE require its effector domain, but not PIP3. Our findings reveal a critical role for Rho GTPases in positioning Ras activation and thereby establishing the accuracy of directional sensing.
Collapse
|
35
|
Sharma VP, Eddy R, Entenberg D, Kai M, Gertler FB, Condeelis J. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Curr Biol 2013; 23:2079-89. [PMID: 24206842 DOI: 10.1016/j.cub.2013.08.044] [Citation(s) in RCA: 130] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Revised: 07/17/2013] [Accepted: 08/14/2013] [Indexed: 01/31/2023]
Abstract
BACKGROUND Tks5 regulates invadopodium formation, but the precise timing during invadopodium lifetime (initiation, stabilization, maturation) when Tks5 plays a role is not known. RESULTS We report new findings based on high-resolution spatiotemporal live-cell imaging of invadopodium precursor assembly. Cortactin, N-WASP, cofilin, and actin arrive together to form the invadopodium precursor, followed by Tks5 recruitment. Tks5 is not required for precursor initiation but is needed for precursor stabilization, which requires the interaction of the phox homology (PX) domain of Tks5 with PI(3,4)P2. During precursor formation, PI(3,4)P2 is uniformly distributed but subsequently starts accumulating at the precursor core 3-4 min after core initiation, and conversely, PI(3,4,5)P3 gets enriched in a ring around the precursor core. SHIP2, a 5'-inositol phosphatase, localizes at the invadopodium core and regulates PI(3,4)P2 levels locally at the invadopodium. The timing of SHIP2 arrival at the invadopodium precursor coincides with the onset of PI(3,4)P2 accumulation. Consistent with its late arrival, we found that SHIP2 inhibition does not affect precursor formation but does cause decreases in mature invadopodia and matrix degradation, whereas SHIP2 overexpression increases matrix degradation. CONCLUSIONS Together, these findings lead us to propose a new sequential model that provides novel insights into molecular mechanisms underlying invadopodium precursor initiation, stabilization, and maturation into a functional invadopodium.
Collapse
Affiliation(s)
- Ved P Sharma
- Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
| | | | | | | | | | | |
Collapse
|
36
|
Awad A, Sar S, Barré R, Cariven C, Marin M, Salles JP, Erneux C, Samuel D, Gassama-Diagne A. SHIP2 regulates epithelial cell polarity through its lipid product, which binds to Dlg1, a pathway subverted by hepatitis C virus core protein. Mol Biol Cell 2013; 24:2171-85. [PMID: 23699395 PMCID: PMC3708724 DOI: 10.1091/mbc.e12-08-0626] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The main targets of hepatitis C virus (HCV) are hepatocytes, the highly polarized cells of the liver, and all the steps of its life cycle are tightly dependent on host lipid metabolism. The interplay between polarity and lipid metabolism in HCV infection has been poorly investigated. Signaling lipids, such as phosphoinositides (PIs), play a vital role in polarity, which depends on the distribution and expression of PI kinases and PI phosphatases. In this study, we report that HCV core protein, expressed in Huh7 and Madin-Darby canine kidney (MDCK) cells, disrupts apicobasal polarity. This is associated with decreased expression of the polarity protein Dlg1 and the PI phosphatase SHIP2, which converts phosphatidylinositol 3,4,5-trisphosphate into phosphatidylinositol 4,5-bisphosphate (PtdIns(3,4)P2). SHIP2 is mainly localized at the basolateral membrane of polarized MDCK cells. In addition, PtdIns(3,4)P2 is able to bind to Dlg1. SHIP2 small interfering RNA or its catalytically dead mutant disrupts apicobasal polarity, similar to HCV core. In core-expressing cells, RhoA activity is inhibited, whereas Rac1 is activated. Of interest, SHIP2 expression rescues polarity, RhoA activation, and restricted core level in MDCK cells. We conclude that SHIP2 is an important regulator of polarity, which is subverted by HCV in epithelial cells. It is suggested that SHIP2 could be a promising target for anti-HCV treatment.
Collapse
Affiliation(s)
- Aline Awad
- Université Paris-Sud, UMR-S 785, F-94800 Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Xie J, Erneux C, Pirson I. How does SHIP1/2 balance PtdIns(3,4)P2 and does it signal independently of its phosphatase activity? Bioessays 2013; 35:733-43. [PMID: 23650141 DOI: 10.1002/bies.201200168] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The number of cellular events identified as being directly or indirectly modulated by phosphoinositides dramatically increased in the recent years. Part of the complexity results from the fact that the seven phosphoinositides play second messenger functions in many different areas of growth factors and insulin signaling, cytoskeletal organization, membrane dynamics, trafficking, or nuclear signaling. PtdIns(3,4)P2 is commonly reported as a product of the SH2 domain-containing inositol 5-phosphatases 1/2 (SHIP1 and SHIP2) that dephosphorylate PtdIns(3,4,5)P3 at the 5-position. Here we discuss recent interest in PtdIns(3,4)P2 signaling highlighting its involvement in key cellular mechanisms such as cell adhesion, migration, and cytoskeletal regulation. We question and discuss the involvement of SHIP2 either as a PI 5-phosphatase or as a scaffold protein in insulin signaling, cytoskeletal dynamics, and endocytosis of growth factor receptors.
Collapse
Affiliation(s)
- Jingwei Xie
- Department of Pathophysiology, China Medical University, Heping District, Shenyang Liaoning Province, China
| | | | | |
Collapse
|
38
|
Elong Edimo W, Vanderwinden JM, Erneux C. SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. Adv Biol Regul 2013; 53:28-37. [PMID: 23040614 DOI: 10.1016/j.jbior.2012.09.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Accepted: 09/04/2012] [Indexed: 06/01/2023]
Abstract
Phosphoinositide 5-phosphatases are critical enzymes in modulating the concentrations of PI(3,4,5)P(3), PI(4,5)P(2) and PI(3,5)P(2). The SH2 domain containing inositol 5-phosphatases SHIP1 and SHIP2 belong to this family of enzymes very much involved in physiopathology and development. Therefore activity and localization of the enzymes are particularly important taking into account both catalytic and non-catalytic mechanisms of the SHIP phosphatases. Several different mechanisms have been reported for SHIP2 targeting that often result from specific protein:protein interactions. In unstimulated astrocytoma cells, SHIP2 has a perinuclear and cytoplasmic localization. In serum-stimulated cells, SHIP2 can be localized at the plasma membrane and at focal contacts in polarized cells. A phosphorylated form of SHIP2 on S132 can be found in the nucleus and nuclear speckles. When present at the plasma membrane, SHIP2 may control the intracellular level of PI(3,4,5)P(3) thereby producing PI(3,4)P(2). When present in the nucleus, SHIP2 probably associates to other nuclear proteins such as lamin A/C and could potentially control nuclear PI(4,5)P(2). Finally, its presence at focal adhesions and lamellipodia could suggest a role in cell adhesion and migration. It is proposed that the complex phenotype observed in SHIP2 mutant mice in tissue development and growth could result from the addition of plasma membrane and nuclear effects consecutive to SHIP2 alteration.
Collapse
Affiliation(s)
- William's Elong Edimo
- Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Campus Erasme, Bldg. C, 808 Route de Lennik, 1070 Brussels, Belgium
| | | | | |
Collapse
|
39
|
Iwai LK, Chang F, Huang PH. Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adh Migr 2012; 7:161-4. [PMID: 23154445 PMCID: PMC3725701 DOI: 10.4161/cam.22572] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
|